行情

CLDX

CLDX

塞德斯医疗
NASDAQ

实时行情|Nasdaq Last Sale

2.290
-0.100
-4.18%
已收盘, 17:08 11/12 EST
开盘
2.570
昨收
2.390
最高
2.570
最低
2.250
成交量
24.06万
成交额
--
52周最高
11.62
52周最低
2.010
市值
3,439.26万
市盈率(TTM)
-0.6160
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLDX 新闻

  • Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
  • Zacks.23小时前
  • Celldex Therapeutics Q3 EPS $(0.75) Beats $(0.84) Estimate
  • Benzinga.1天前
  • Celldex Provides Corporate Update and Reports Third Quarter 2019 Results
  • GlobeNewswire.1天前
  • Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs
  • GlobeNewswire.2天前

更多

所属板块

生物技术和医学研究
+0.28%
制药与医学研究
+0.27%

热门股票

名称
价格
涨跌幅

CLDX 简况

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
展开

Webull提供Celldex Therapeutics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。